Curant Health Director of Clinical Services Vickie Andros shares her HIV therapy insights with Managed Healthcare Executive
Advancements in HIV treatment over the past 20 years or so have been absolutely remarkable. When demonstrating excellent adherence to medication therapy, people living with HIV are managing it like a common, chronic condition experiencing increasing longevity of life.
While science has yet to create a cure for HIV, there are new therapies in the pipeline that may prove capable of improving quality of life for those living with HIV further still including Juluca (Janssen Therapeutics, ViiV Healthcare) the first two-drug regimen to treat certain adults with HIV-1 infections.
Additionally, contributing author Erin Bastik, PharmD, RPh, writes, “At press time, FDA approved Gilead Sciences Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), a once-daily single-tablet regimen for the treatment of HIV-1 infection.”
Curant Health Director of Clinical Services Vickie Andros, PharmD, shared her insights into the latest therapies in the HIV pipeline with Managed Healthcare Executive in the March 2018 issue. Catch all of the insights in Managed Healthcare Executive here.
If you represent a 340B covered entity or a managed care organization seeking to improve adherence to patients on complicated medication regimens, we want to talk! Email Amber Adams at aadams@curanthealth.com.